We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

By LabMedica International staff writers
Posted on 27 May 2026

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight MRD test in EMBO Molecular Medicine on May 26, 2026. More...

Titled “NeoCircle: Pre- and Post-Operative Circulating Tumor DNA Dynamics Predicts Survival in Neoadjuvant-Treated Early Breast Cancer,” the study highlights the role of ultrasensitive molecular residual disease (MRD) detection in early breast cancer management.

Conducted by researchers at Lund University (Lund, Sweden), the NeoCircle study monitored 136 early breast cancer patients eligible for neoadjuvant therapy (NAT) within the SCAN‑B study across all subtypes. Complete or partial clearance of circulating tumor DNA (ctDNA) during NAT was associated with 10.4% recurrence versus 56.3% among non‑responders. Lack of clearance after therapy predicted poorer breast cancer‑free interval and overall survival compared with pathologic complete response. 

During post-surgical adjuvant monitoring, ctDNA detection preceded relapse up to four years earlier, with a median lead time of 13.8 months. Overall sensitivity for distant recurrence was 86.7%, rising to 92.9% for pathologically confirmed cases and reaching 81.0% when local and CNS-only relapses were included. The findings validate structural variants (SVs) as clinically relevant MRD biomarkers in early breast cancer, showing that ctDNA monitoring across neoadjuvant and adjuvant treatment can predict disease progression months to years in advance and offer insight into clinical outcomes, including survival.

SAGA Diagnostics’ Pathlight MRD is a personalized, tumor-informed, multi-cancer MRD platform designed for ultrasensitive detection of ctDNA. Using a proprietary combination of whole-genome sequencing and digital PCR, Pathlight tracks SVs, stable genomic biomarkers that can support earlier and more precise detection of cancer recurrence and treatment response monitoring.

“With unmatched sensitivity, detecting structural variants at levels as low as 1 part in 10 million, Pathlight provides the resolution needed to identify true molecular residual disease at its earliest stages,” said Lao Saal, MD, PhD, Head, Division of Translational Oncogenomics, and Co-Director, CIRCE Women’s Cancer Research Center, Lund University. “The NeoCircle study, with up to 9.7 years of clinical follow-up, offers a comprehensive view of the durability of SVs and the potential for clinical impact incorporating this approach in the care plan for patients with cancer.”

"SVs represent a foundational biomarker for detecting molecular recurrence before it becomes clinically apparent. The early origin of SVs in tumorigenesis, stability under treatment pressure, and resistance to confounding signals enable ultra-sensitive, tumor-informed detection," said Wendy Levin, MD MS, Chief Clinical Officer of SAGA Diagnostics.

"With 85% of patients in this analysis having Stage I-II disease, where curative intent remains high, we see a clear path toward integrating these biomarkers into clinical practice. This can help guide treatment decisions in real-time, with the potential to improve patient outcomes, including long-term survival," said Dr. Levin.

Related Links
Lund University
SAGA Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.